Treatment for children and adults, Healing of NSAID-Associated Gastric Ulcer
Lansoprazole Enteric-coated (Pellets) Capsules boast the highest bioavailability in all of the proton pump inhibitors and the absorption of lansoprazole is rapid and relatively complete with absolute bioavailability over 80%. A preclinical study suggests that, besides the inhibition of acid secretion, Lansoprazole protection against NSAID-induced gastric damage depends on a reduction in mucosal oxidative injury. The safety and effectiveness of Lansoprazole have been established in pediatric patients 1 to 17 years of age for treatment of symptomatic GERD and erosive esophagitis and Lansoprazole has been approved for the treatment for children by FDA.

-> Returns